David Hoey Email & Phone Number

Vaxxas is focused on enhancing the performance of existing and next generation vaccines with its proprietary Nanopatch™ technology platform. Vaxxas’ Nanopatch contains an ultra-high density array of projections – invisible to the naked human eye – that are dry-coated with vaccine. Application of the Nanopatch to the skin is pain free and rapidly delivers the vaccine to the abundant immune cell population immediately below the skin surface. Preclinical studies have shown that Nanopatch delivery of vaccine achieves equivalent protective immunity as the needle and syringe – but with only one hundredth (1/100th) of the dose. Vaxxas is applying its technology to improve the performance of vaccines, with initial applications targeting infectious disease and oncology.